The FDA tells Endpoints News today that it’s aware of the death of a patient taking Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) and is “actively investigating” the case. Their statement follows the latest comments from RBC analyst Brian Abrahams, who is back with an update on the death, and this time he says that there … Continue reading Exclusive: FDA probing death of Aduhelm patient as Biogen’s Alzheimer’s drug continues to stir controversy